1. Home
  2. KALU vs IOVA Comparison

KALU vs IOVA Comparison

Compare KALU & IOVA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Kaiser Aluminum Corporation

KALU

Kaiser Aluminum Corporation

N/A

Current Price

$121.31

Market Cap

1.9B

Sector

Industrials

ML Signal

N/A

Logo Iovance Biotherapeutics Inc.

IOVA

Iovance Biotherapeutics Inc.

N/A

Current Price

$4.03

Market Cap

2.1B

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
KALU
IOVA
Founded
1946
2007
Country
United States
United States
Employees
N/A
N/A
Industry
Metal Fabrications
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Industrials
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.9B
2.1B
IPO Year
2006
2008

Fundamental Metrics

Financial Performance
Metric
KALU
IOVA
Price
$121.31
$4.03
Analyst Decision
Buy
Buy
Analyst Count
3
10
Target Price
$107.00
$9.11
AVG Volume (30 Days)
205.8K
15.8M
Earning Date
01-01-0001
05-25-2026
Dividend Yield
2.41%
N/A
EPS Growth
135.89
14.84
EPS
6.77
N/A
Revenue
$1,585,900,000.00
N/A
Revenue This Year
$13.37
$49.14
Revenue Next Year
$2.62
$51.69
P/E Ratio
$18.84
N/A
Revenue Growth
N/A
N/A
52 Week Low
$46.81
$1.64
52 Week High
$150.00
$5.63

Technical Indicators

Market Signals
Indicator
KALU
IOVA
Relative Strength Index (RSI) 41.11 54.58
Support Level $116.89 $1.99
Resistance Level $136.10 $4.34
Average True Range (ATR) 5.68 0.48
MACD -1.30 0.06
Stochastic Oscillator 20.12 42.91

Price Performance

Historical Comparison
KALU
IOVA

About KALU Kaiser Aluminum Corporation

Kaiser Aluminum Corp produces and sells semi-fabricated specialty aluminum products predominantly to industrial customers. Its products include fabricated aluminum mill products such as flat-rolled (plate, sheet, and coil), extruded (rod, bar, hollows, and shapes), drawn (rod, bar, pipe, tube and wire) and certain cast aluminum products. Geographically, the company generates majority of its revenue from the United States.

About IOVA Iovance Biotherapeutics Inc.

Iovance Biotherapeutics Inc is a clinical-stage biopharmaceutical company, pioneering a transformational approach to treating cancer by harnessing the human immune system's ability to recognize and destroy diverse cancer cells using therapies personalized for each patient. The company is preparing for potential U.S. regulatory approvals and commercialization of the first autologous T-cell therapy to address a solid tumor cancer. It operates in one segment, focusing on innovating, developing, and commercializing therapies using its autologous TIL cell therapies for patients with solid tumor cancers. Geographically, the company operates in United States and Rest of the World.

Share on Social Networks: